Home/Lead Pharma/Arthur Oubrie, PhD

AO

Arthur Oubrie, PhD

Chief Scientific Officer

Therapeutic Areas

Autoimmune Diseases Cancer

Lead Pharma Pipeline

Drug	Indication	Phase
RORγt Inhibitor (SAR441169)	Autoimmune Diseases (Immunology)	Phase I/II
ERRα Program	Cancer	Pre-clinical

Leadership Team at Lead Pharma

Frans van den Berg, MSc, MBA

Chief Executive Officer

View full Lead Pharma profile